Gennaro Pagano, MD, MSc, PhD, F. Hoffmann – La Roche Ltd, Basel, Switzerland, talks about the potential of broadening clinical trial outcomes in Parkinson’s disease beyond traditional rating scales. Currently, disease progression is measured using the Unified Parkinson’s Disease Rating Scale (UPDRS). The UPDRS was developed to capture the global status of patients in clinical assessments, but it wasn’t validated to be used as a total score in interventional trials. Different entities are now developing novel biomarkers to measure disease progression objectively and new patient-reported outcomes focused on the early disease stages. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Dr Pagano is a full-time employee and shareholder at F. Hoffmann – La Roche Ldt.
